MindMaze Therapeutics Holding SA MMTZF
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each CHF of equity lost 99 cents this year.
The 3-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue CHF B | 0.0 | 0.0 | 0.0 |
| Operating income CHF B | −0.1 | −0.1 | −0.0 |
| EBITDA CHF B | −0.1 | −0.0 | −0.0 |
| Income tax CHF B | −0.0 | −0.0 | −0.0 |
| Net income CHF B | −0.1 | −0.1 | −0.0 |
| Free cash flow CHF B | −0.0 | −0.0 | −0.0 |
| EPS, diluted CHF | −8.35 | −4.80 | −0.01 |
| Dividend / sh CHF | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — |
| ROE % | −99.4 | −31.1 | −19.1 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 3 of the 3 fiscal years we could check. 28 checks were skipped: the balance sheet is not tagged before 2021. 14 checks were skipped: EPS is not tagged before 2021.